
Alain Rolland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6221389/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. Journal of Controlled Release, 1998, 56, 259-272.	9.9	569
2	Highly cited research articles in Journal of Controlled Release: Commentaries and perspectives by authors. Journal of Controlled Release, 2014, 190, 29-74.	9.9	394
3	Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Biotechnology, 1999, 17, 343-348.	17.5	283
4	Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharmaceutical Research, 1996, 13, 701-709.	3.5	200
5	Cationic lipid-based gene delivery systems: pharmaceutical perspectives. Pharmaceutical Research, 1997, 14, 853-859.	3.5	200
6	Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharmaceutical Research, 1993, 10, 1738-1744.	3.5	184
7	Biodistribution and Gene Expression of Lipid/Plasmid Complexes after Systemic Administration. Human Gene Therapy, 1998, 9, 2083-2099.	2.7	160
8	Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects. Journal of Infectious Diseases, 2008, 197, 1634-1642.	4.0	136
9	Pharmaceutical Perspectives of Nonviral Gene Therapy. Advances in Genetics, 1999, 41, 95-156.	1.8	126
10	Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. Journal of Controlled Release, 1998, 52, 191-203.	9.9	110
11	A Physicochemical Approach for Predicting the Effectiveness of Peptide-Based Gene Delivery Systems for Use in Plasmid-Based Gene Therapy. Biophysical Journal, 1998, 74, 2802-2814.	0.5	105
12	Vaxfectinâ"¢-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge. Hum Vaccin, 2007, 3, 157-164.	2.4	79
13	Gene medicines: The end of the beginning?. Advanced Drug Delivery Reviews, 2005, 57, 669-673.	13.7	76
14	Plasmid DNA–Based Vaccines Protect Mice and Ferrets against Lethal Challenge with A/Vietnam/1203/04 (H5N1) Influenza Virus. Journal of Infectious Diseases, 2008, 197, 1643-1652.	4.0	69
15	Expression of Biologically Active Human Insulin-like Growth Factor-I Following Intramuscular Injection of a Formulated Plasmid in Rats. Human Gene Therapy, 1997, 8, 1785-1795.	2.7	58
16	Plasmid delivery to muscle:. Advanced Drug Delivery Reviews, 1998, 30, 151-172.	13.7	56
17	Systemic Effect of Human Growth Hormone after Intramuscular Injection of a Single Dose of a Muscle-Specific Gene Medicine. Human Gene Therapy, 1998, 9, 659-670.	2.7	54
18	Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opinion on Drug Delivery, 2010, 7, 1433-1446.	5.0	51

ALAIN ROLLAND

#	Article	IF	CITATIONS
19	I. Poloxamer-Formulated Plasmid DNA-Based Human Cytomegalovirus Vaccine: Evaluation of Plasmid DNA Biodistribution/Persistence and Integration. Human Gene Therapy, 2005, 16, 1143-1150.	2.7	44
20	Target specific optimization of cationic lipid-based systems for pulmonary gene therapy. Pharmaceutical Research, 1998, 15, 1340-1347.	3.5	43
21	Blood Clearance and Organ Distribution of Intravenously Administered Polymethacrylic Nanoparticles in Mice. Journal of Pharmaceutical Sciences, 1989, 78, 481-484.	3.3	41
22	Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharmaceutical Research, 1999, 16, 889-895.	3.5	39
23	Physical characterization and <i>in vivo</i> evaluation of poloxamerâ€based DNA vaccine formulations. Journal of Gene Medicine, 2008, 10, 770-782.	2.8	38
24	Preface. Advanced Drug Delivery Reviews, 1998, 30, 1-3.	13.7	35
25	Use of Vaxfectin Adjuvant with DNA Vaccine Encoding the Measles Virus Hemagglutinin and Fusion Proteins Protects Juvenile and Infant Rhesus Macaques against Measles Virus. Vaccine Journal, 2008, 15, 1214-1221.	3.1	35
26	Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. Journal of General Virology, 2012, 93, 1305-1315.	2.9	35
27	Flow cytometric quantitative evaluation of phagocytosis by human mononuclear and polymorphonuclear cells using fluorescent nanoparticles. Journal of Immunological Methods, 1987, 96, 185-193.	1.4	31
28	A new immunoreagent for cell labeling CD3 monoclonal antibody covalently coupled to fluorescent polymethacrylic nanoparticles. Journal of Immunological Methods, 1988, 106, 161-167.	1.4	31
29	Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial. Vaccines, 2013, 1, 398-414.	4.4	31
30	Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline. International Journal of Pharmaceutics, 1989, 54, 113-121.	5.2	30
31	Effect of penetration enhancers on the phase transition of multilamellar liposomes of dipalmitoylphosphatidylcholine. A study by differential scanning calorimetry. International Journal of Pharmaceutics, 1991, 76, 217-224.	5.2	29
32	Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes. International Journal of Pharmaceutics, 1987, 39, 173-180.	5.2	25
33	Modulation of Cellular Cholesterol and Its Effect on Cornified Envelope Formation in Cultured Human Epidermal Keratinocytes. Journal of Investigative Dermatology, 1991, 97, 771-775.	0.7	25
34	Nuclear gene delivery: the Trojan horse approach. Expert Opinion on Drug Delivery, 2006, 3, 1-10.	5.0	25
35	Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration. Pharmaceutical Research, 1998, 15, 1743-1747.	3.5	24
36	Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin, 2009, 5, 536-544.	2.4	22

Alain Rolland

#	Article	IF	CITATIONS
37	Vaxfectin®, a cationic lipid-based adjuvant for protein-based influenza vaccines. Vaccine, 2009, 27, 6399-6403.	3.8	20
38	ll. Cationic Lipid-Formulated Plasmid DNA-Based Bacillus anthracis Vaccine: Evaluation of Plasmid DNA Persistence and Integration Potential. Human Gene Therapy, 2005, 16, 1151-1156.	2.7	17
39	Vaxfectin Adjuvant Improves Antibody Responses of Juvenile Rhesus Macaques to a DNA Vaccine Encoding the Measles Virus Hemagglutinin and Fusion Proteins. Journal of Virology, 2013, 87, 6560-6568.	3.4	17
40	Pharmacokinetics and tissue distribution of doxorubicin-loaded polymethacrylic nanoparticles in rabbits. International Journal of Pharmaceutics, 1988, 42, 145-154.	5.2	16
41	Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Human Vaccines and Immunotherapeutics, 2012, 8, 1595-1606.	3.3	14
42	Vaccination with Polymerase Chain Reaction-Generated Linear Expression Cassettes Protects Mice Against Lethal Influenza A Challenge. Human Gene Therapy, 2007, 18, 763-771.	2.7	13
43	Influence of formulation, receptor fluid, and occlusion, on in vitro drug release from topical dosage forms, using an automated flow-through diffusion cell. Pharmaceutical Research, 1992, 09, 82-86.	3.5	12
44	Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®. Vaccine, 2011, 29, 5443-5452.	3.8	12
45	Synthetic glycopeptide-based delivery systems for systemic gene targeting to hepatocytes. Pharmaceutical Research, 2000, 17, 451-459.	3.5	10
46	Plasmid Vaccines and Therapeutics: From Design to Applications. , 2005, 99, 41-92.		10
47	A TaqMan® Reverse Transcription Polymerase Chain Reaction (RT-PCR) InÂVitro Potency Assay for Plasmid-based Vaccine Products. Molecular Biotechnology, 2008, 40, 47-57.	2.4	10
48	Analysis of biomarkers after intramuscular injection of Vaxfectin®-formulated hCMV gB plasmid DNA. Vaccine, 2009, 27, 7409-7417.	3.8	10
49	Preclinical evaluation of Vaxfectin®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 1333-1345.	3.3	9
50	Increase of doxorubicin penetration in cultured rat hepatocytes by its binding to polymethacrylic nanoparticles. International Journal of Pharmaceutics, 1989, 53, 67-73.	5.2	8
51	Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy. Cancer Gene Therapy, 2001, 8, 55-62.	4.6	8
52	Development of anthrax DNA vaccines. Current Opinion in Molecular Therapeutics, 2004, 6, 506-12.	2.8	6
53	Determination of the surface tension of block copolymer micelles by phagocytosis. Pharmaceutical Research, 1995, 12, 1435-1438.	3.5	2
54	RAPID DEVELOPMENT OF A VAXFECTIN®-ADJUVANTED DNA VACCINE ENCODING PANDEMIC SWINE-ORIGIN INFLUENZA A VIRUS (H1N1) HEMAGGLUTININ. Gene Therapy and Regulation, 2009, 04, 45-55.	0.3	1

Alain Rolland

#	Article	IF	CITATIONS
55	Pharmaceutical Gene Medicines for Local and Systemic Therapy. Nature Biotechnology, 1999, 17, 26-26.	17.5	Ο
56	II. Cationic Lipid-Formulated Plasmid DNA-Based Bacillus anthracis Vaccine: Evaluation of Plasmid DNA Persistence and Integration Potential. Human Gene Therapy, 2005, .	2.7	0
57	I. Poloxamer-Formulated Plasmid DNA-Based Human Cytomegalovirus Vaccine: Evaluation of Plasmid DNA Biodistribution/Persistence and Integration. Human Gene Therapy, 2005, .	2.7	Ο
58	I. Poloxamer-Formulated Plasmid DNA-Based Human Cytomegalovirus Vaccine: Evaluation of Plasmid DNA Biodistribution/Persistence and Integration. Human Gene Therapy, 2005, .	2.7	0
59	ll. Cationic Lipid-Formulated Plasmid DNA-Based Bacillus anthracis Vaccine: Evaluation of Plasmid DNA Persistence and Integration Potential. Human Gene Therapy, 2005, .	2.7	0